About Us | Contact

Dr. Maria Baer Investigator

Hematology & Oncology University Of Maryland Medical Center NPI1700881802
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$100,255.68
from 45 payments in the last 6 years

Total Cash or Cash Equivalent

$91,491.20
from 5 payments in the last 6 years

Total In-kind Items & Services

$8,764.48
from 40 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
05/20/2021 General (Non-Research) In-kind items and services Compensation for serving as faculty or as a speaker for a medical education program $43.36 Details
Payment from Servier Pharmaceuticals LLC
Payment Record ID 852922553
07/26/2021 Research In-kind items and services Drug $94.58 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation.
Payment Record ID 801077541
01/20/2021 Research In-kind items and services Drug $100.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation.
Payment Record ID 801077539
11/10/2021 Research Cash or cash equivalent $15187.40 Details
Payment from AI Therapeutics, Inc.
Paymment Research Study LAM-003-HEM-CLN02
Payment Record ID 775283707
10/19/2020 Research In-kind items and services Drug $70.83 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319031
10/19/2020 Research In-kind items and services Drug $70.83 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319029
10/19/2020 Research In-kind items and services Drug $100.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319027
09/18/2020 Research In-kind items and services Drug $449.58 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319025
09/18/2020 Research In-kind items and services Drug $70.83 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319023
07/09/2020 Research In-kind items and services Drug $100.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319021
07/09/2020 Research In-kind items and services Drug $100.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319019
06/15/2020 Research In-kind items and services Drug $23.75 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319017
06/15/2020 Research In-kind items and services Drug $22.35 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319015
05/20/2020 Research In-kind items and services Drug $427.21 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319013
05/20/2020 Research In-kind items and services Drug $70.83 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319011
05/20/2020 Research In-kind items and services Drug $53.13 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319009
04/21/2020 Research In-kind items and services Drug $427.71 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319007
03/17/2020 Research In-kind items and services Drug $140.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319005
03/17/2020 Research In-kind items and services Drug $50.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319003
03/17/2020 Research In-kind items and services Drug $151.66 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319001
03/17/2020 Research In-kind items and services Drug $75.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721318999
03/17/2020 Research In-kind items and services Drug $100.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721318997
02/14/2020 Research In-kind items and services Drug $875.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721318995
02/14/2020 Research In-kind items and services Drug $75.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721318993
01/23/2020 Research In-kind items and services Drug $250.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721318991
01/23/2020 Research In-kind items and services Drug $75.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721318989
01/23/2020 Research In-kind items and services Drug $70.59 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721318987
07/28/2020 Research Cash or cash equivalent $19554.20 Details
Payment from AI Therapeutics, Inc.
Paymment Research Study LAM-003-HEM-CLN02
Payment Record ID 714314439
12/08/2019 General (Non-Research) In-kind items and services Food and Beverage $140.00 Details
Payment from Agios Pharmaceuticals, Inc.
Payment Record ID 701352241
12/07/2019 Research In-kind items and services Drug $57.03 Details
Payment from AbbVie, Inc.
Paymment Research Study M15-531
Clinical Trials Gov ID NCT02942290
Payment Record ID 647628827
10/22/2019 Research In-kind items and services Drug $431.25 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386121
10/22/2019 Research In-kind items and services Drug $290.32 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386113
09/18/2019 Research In-kind items and services Drug $375.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386105
05/15/2019 Research In-kind items and services Drug $608.82 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386101
03/25/2019 Research In-kind items and services Drug $517.24 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386093
03/25/2019 Research In-kind items and services Drug $533.33 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386083
02/13/2019 Research In-kind items and services Drug $883.33 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386075
02/13/2019 Research In-kind items and services Drug $324.56 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386067
01/09/2019 Research In-kind items and services Drug $190.26 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386057
10/24/2019 Research Cash or cash equivalent $40064.40 Details
Payment from AI Therapeutics, Inc.
Paymment Research Study LAM 003-HEM-CLN02
Payment Record ID 624094975
11/30/2018 General (Non-Research) In-kind items and services Food and Beverage $113.37 Details
Payment from Kite Pharma, Inc.
Payment Record ID 574212143
12/02/2018 General (Non-Research) In-kind items and services Food and Beverage $116.08 Details
Payment from Amgen Inc.
Payment Record ID 567615295
06/01/2018 Research Cash or cash equivalent $16210.00 Details
Payment from AI Therapeutics, Inc.
Paymment Research Study LAM-003-HEM CLN02
Payment Record ID 539595141
12/02/2016 General (Non-Research) In-kind items and services Food and Beverage $96.65 Details
Payment from Pfizer Inc.
Payment Record ID 404666578
02/26/2016 Research Cash or cash equivalent $475.20 Details
Payment from Daiichi Sankyo Inc.
Paymment Research Study AC220-007
Clinical Trials Gov ID NCT02039726
Payment Record ID 386942783
;